Jonathan Zoghby, MD
Ophthalmology · Oxford, MSNPI 1962631150
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.7% of the total across 278 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 32 manufacturers, the largest accounting for just 15.0% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,482, 3.4 times the $441 reported in 2019.
Across 278 payments — averaging $19.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$828
- Alcon$747
- Mallinckrodt Hospital Products Inc.$457
- Amgen$384
- Glaukos Corporation$363
- Johnson & Johnson Surgical Vision, Inc.$336
- plus $2K from 26 others
What the payments were for
- Speaking & faculty fees$391%
- Food & beverage$5,33297%
- Education$401%
- Gifts$451%
- Entertainment$551%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 39 | $828 |
| Alcon | 46 | $747 |
| Mallinckrodt Hospital Products Inc. | 21 | $457 |
| Amgen(2 entities) | 20 | $384 |
| Glaukos Corporation | 12 | $363 |
| Johnson & Johnson Surgical Vision, Inc. | 15 | $336 |
| Rxsight Inc | 11 | $270 |
| Sight Sciences, Inc. | 12 | $258 |
| Oyster Point Pharma, Inc. | 11 | $224 |
| Bausch & Lomb Americas Inc. | 10 | $218 |
| Rayner Intraocular Lenses Limited | 11 | $202 |
| Novartis | 11 | $180 |
| Omeros Corporation | 9 | $127 |
| Ivantis, Inc | 6 | $103 |
| Aerie Pharmaceuticals, Inc. | 5 | $86 |
| ANI Pharmaceuticals, Inc. | 4 | $77 |
| Thea Pharma Inc. | 4 | $75 |
| Nova Eye, Inc. | 2 | $68 |
| Sun Pharmaceutical Industries Inc. | 3 | $64 |
| Iridex Corporation | 4 | $63 |
| NEW World Medical,inc. | 4 | $51 |
| Biotissue Holdings Inc. | 3 | $49 |
| Eyepoint US, Inc. | 3 | $46 |
| Dompe US, Inc. | 2 | $38 |
| Genentech USA, Inc. | 2 | $38 |
| Beaver-visitec International, Inc. | 2 | $32 |
| Apellis Pharmaceuticals, Inc. | 1 | $26 |
| Tarsus Pharmaceuticals, Inc. | 1 | $26 |
| Ocular Therapeutix, Inc. | 1 | $24 |
| Harrow Eye, LLC | 1 | $21 |
| Halozyme Inc | 1 | $18 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,512 in reported general payments places this provider in the 80th percentile of 150 ophthalmology providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 154 | $69,638 |
| Prednisolone Acetate | 659 | $27,434 |
| CombiganBrimonidine Tartrate/Timolol | 39 | $18,686 |
| Brimonidine Tartrate | 599 | $16,887 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 947 | $15,410 |
| Latanoprost | 1,167 | $11,424 |
| VyzultaLatanoprostene Bunod | 15 | $8,608 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 40 | $7,863 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 28 | $7,460 |
| Ketorolac Tromethamine | 406 | $7,330 |
| RhopressaNetarsudil Mesylate | 18 | $6,210 |
| Pilocarpine Hcl | 86 | $4,924 |
| Alphagan PBrimonidine Tartrate | 15 | $4,467 |
| Travoprost | 41 | $3,423 |
| Atropine Sulfate | 100 | $3,418 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Combigan, Alphagan P | $828 | $92,791208 claims |
| Bausch & Lomb Americas Inc.Vyzulta | $218 | $8,60815 claims |
| AlconSimbrinza | $747 | $7,46028 claims |
| Aerie Pharmaceuticals, Inc.Rhopressa | $86 | $6,21018 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 150 ophthalmology providers in Mississippi.
Other ophthalmology in Oxford
- James ShippOxford$21K
- Thomas TannOxford$4K
- William FarmerOxford$4K
- Blake BoothOxford$4K
- Kiper NelsonHattiesburg$234K
- John ParkerTupelo$72K
- Joseph ChildsTupelo$42K
- Heather HancockJackson$39K
- Leslie AdenFlowood$38K
- Adam QuinnHattiesburg$29K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.